We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Taro Cited for GMP Violations at Canadian Facility
Taro Cited for GMP Violations at Canadian Facility
March 2, 2009
The FDA has expressed concern that stability failures and other out-of-specification results for Taro Pharmaceutical’s creams did not lead the generic-drug maker to withdraw the products or shorten the expiration period on them, according to a warning letter.